Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112194519 | 11219451 | 9 | F | 20150606 | 20160725 | 20150625 | 20160801 | EXP | US-PFIZER INC-2015209319 | PFIZER | 36.00 | YR | F | Y | 72.00000 | KG | 20160801 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112194519 | 11219451 | 1 | PS | BOSULIF | BOSUTINIB MONOHYDRATE | 1 | Oral | 500 MG, 1X/DAY | Y | L14289 | 203341 | 500 | MG | FILM-COATED TABLET | QD | ||||
| 112194519 | 11219451 | 2 | SS | BOSULIF | BOSUTINIB MONOHYDRATE | 1 | Oral | 500 MG, DAILY | Y | L51281 | 203341 | 500 | MG | FILM-COATED TABLET | |||||
| 112194519 | 11219451 | 3 | SS | BOSULIF | BOSUTINIB MONOHYDRATE | 1 | Oral | 500 MG, 1X/DAY | Y | L51281 | 203341 | 500 | MG | FILM-COATED TABLET | QD | ||||
| 112194519 | 11219451 | 4 | SS | BOSULIF | BOSUTINIB MONOHYDRATE | 1 | Oral | 100 MG, 3X/DAY | Y | M04436 | 203341 | 100 | MG | FILM-COATED TABLET | TID | ||||
| 112194519 | 11219451 | 5 | SS | BOSULIF | BOSUTINIB MONOHYDRATE | 1 | UNK | Y | M69064 | 203341 | FILM-COATED TABLET | ||||||||
| 112194519 | 11219451 | 6 | SS | BOSULIF | BOSUTINIB MONOHYDRATE | 1 | Oral | 300 MG, 1X/DAY | Y | M99409 | 203341 | 300 | MG | FILM-COATED TABLET | QD | ||||
| 112194519 | 11219451 | 7 | SS | BOSULIF | BOSUTINIB MONOHYDRATE | 1 | Oral | 300 MG, DAILY | Y | N34110 | 203341 | 300 | MG | FILM-COATED TABLET | |||||
| 112194519 | 11219451 | 8 | SS | BOSULIF | BOSUTINIB MONOHYDRATE | 1 | 400 MG, DAILY | Y | 203341 | 400 | MG | FILM-COATED TABLET | |||||||
| 112194519 | 11219451 | 9 | SS | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | 20 MG, DAILY | U | 0 | 20 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 112194519 | 11219451 | 1 | Chronic myeloid leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 112194519 | 11219451 | HO |
| 112194519 | 11219451 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 112194519 | 11219451 | Abdominal pain upper | |
| 112194519 | 11219451 | Asthenia | |
| 112194519 | 11219451 | Dehydration | |
| 112194519 | 11219451 | Diarrhoea | |
| 112194519 | 11219451 | Fatigue | |
| 112194519 | 11219451 | Gait disturbance | |
| 112194519 | 11219451 | Gastrointestinal disorder | |
| 112194519 | 11219451 | Herpes zoster | |
| 112194519 | 11219451 | Lymph node pain | |
| 112194519 | 11219451 | Lymphadenopathy | |
| 112194519 | 11219451 | Migraine | |
| 112194519 | 11219451 | Muscle spasms | |
| 112194519 | 11219451 | Musculoskeletal stiffness | |
| 112194519 | 11219451 | Nausea | |
| 112194519 | 11219451 | Pain in extremity | |
| 112194519 | 11219451 | Peripheral swelling | |
| 112194519 | 11219451 | Rash generalised | |
| 112194519 | 11219451 | Swelling | |
| 112194519 | 11219451 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 112194519 | 11219451 | 1 | 20150530 | 0 | ||
| 112194519 | 11219451 | 2 | 20150601 | 20150929 | 0 | |
| 112194519 | 11219451 | 3 | 20150701 | 0 | ||
| 112194519 | 11219451 | 4 | 20150601 | 0 | ||
| 112194519 | 11219451 | 5 | 20151127 | 0 | ||
| 112194519 | 11219451 | 6 | 20151127 | 0 | ||
| 112194519 | 11219451 | 7 | 20150601 | 0 | ||
| 112194519 | 11219451 | 8 | 20151030 | 0 |